275 related articles for article (PubMed ID: 28552213)
1. Pricing increases for cancer drugs sparks investigation.
Venkatesan P
Lancet Oncol; 2017 Jul; 18(7):e372. PubMed ID: 28552213
[No Abstract] [Full Text] [Related]
2. Having "Skin in the Game" and Allowing Cross-Border Importation of Drugs to Lower High Prices of Cancer Drugs.
Kantarjian H; Mathisen MS; Lipton JH
JAMA Oncol; 2015 Sep; 1(6):729-30. PubMed ID: 26182331
[No Abstract] [Full Text] [Related]
3. US trade rep is pressing Indian government to forbid production of generic cancer drug, consortium says.
Cohen D
BMJ; 2014 Nov; 349():g6593. PubMed ID: 25370846
[No Abstract] [Full Text] [Related]
4. Drugs are scarce as mix of programs aims to ease access.
Brower V
J Natl Cancer Inst; 2009 Oct; 101(19):1304-6. PubMed ID: 19755680
[No Abstract] [Full Text] [Related]
5. An Oncologist's Letter to Santa: Bring Me Drugs!
Tempero M
J Natl Compr Canc Netw; 2018 Dec; 16(12):1411. PubMed ID: 30545986
[No Abstract] [Full Text] [Related]
6. Selling Patents to Indian Tribes to Delay the Market Entry of Generic Drugs.
Ablavsky G; Larrimore Ouellette L
JAMA Intern Med; 2018 Feb; 178(2):179-180. PubMed ID: 29297039
[No Abstract] [Full Text] [Related]
7. Folly or volley? Will a dollar $4 pill finally open the healthcare market to competitive pricing?
Sturm AC
Healthc Financ Manage; 2006 Nov; 60(11):120-2. PubMed ID: 17094287
[No Abstract] [Full Text] [Related]
8. Long way down--pharmaceutical companies fear falling off 'patent cliff'.
Sklan A
Pharm Pat Anal; 2012 Jul; 1(3):240. PubMed ID: 24386667
[No Abstract] [Full Text] [Related]
9. Pharmaceuticals and Medical Devices: Business Practices.
Steiner DJ;
Issue Brief Health Policy Track Serv; 2016 Dec; 2016():1-38. PubMed ID: 28252886
[No Abstract] [Full Text] [Related]
10. The London Agreement and the future of parallel imports.
Muir J
Nat Biotechnol; 2008 Aug; 26(8):877-9. PubMed ID: 18688237
[No Abstract] [Full Text] [Related]
11. Competition and the Reference Pricing Scheme for pharmaceuticals.
Ghislandi S
J Health Econ; 2011 Dec; 30(6):1137-49. PubMed ID: 21937137
[TBL] [Abstract][Full Text] [Related]
12. Pharmaceuticals and medical devices: business practices.
Steiner DJ
Issue Brief Health Policy Track Serv; 2013 Dec; ():1-36. PubMed ID: 24482889
[No Abstract] [Full Text] [Related]
13. The ethics and economics of pharmaceutical pricing.
Parker-Lue S; Santoro M; Koski G
Annu Rev Pharmacol Toxicol; 2015; 55():191-206. PubMed ID: 25149920
[TBL] [Abstract][Full Text] [Related]
14. A "Method of Use" to Prevent Generic and Biosimilar Market Entry.
Tu SS; Sarpatwari A
N Engl J Med; 2023 Feb; 388(6):483-485. PubMed ID: 36734878
[No Abstract] [Full Text] [Related]
15. Cancer drug prices and the free-market forces.
Kantarjian H; Zwelling L
Cancer; 2013 Nov; 119(22):3903-5. PubMed ID: 24037953
[No Abstract] [Full Text] [Related]
16. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.
Experts in Chronic Myeloid Leukemia
Blood; 2013 May; 121(22):4439-42. PubMed ID: 23620577
[TBL] [Abstract][Full Text] [Related]
17. Pricing Cancer Drugs: When Does Pricing Become Profiteering?
Kushnick HL
AMA J Ethics; 2015 Aug; 17(8):750-3. PubMed ID: 26270874
[No Abstract] [Full Text] [Related]
18. Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA.
Bennett CL; Sartor OA; Armitage JO; Kantarjian H
Lancet Oncol; 2017 Jan; 18(1):22-23. PubMed ID: 28049571
[No Abstract] [Full Text] [Related]
19. [Free trade agreements make the drugs more expensive].
Jeppsson A
Lakartidningen; 2009 Nov 18-24; 106(47):3181. PubMed ID: 20082499
[No Abstract] [Full Text] [Related]
20. Market spiral pricing of cancer drugs.
Light DW; Kantarjian H
Cancer; 2013 Nov; 119(22):3900-2. PubMed ID: 24002792
[No Abstract] [Full Text] [Related]
[Next] [New Search]
